This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Dose Response and Reproducibility

Janet B. Serle, MD; Jacqueline S. Lustgarten, MD; Erik A. Lippa, MD, PhD; Carl B. Camras, MD; Deborah L. Panebianco, MS; Steven M. Podos, MD

Arch Ophthalmol. 1990;108(6):838-841.

Abstract
• We investigated the dose-response and reproducibility of the intraocular pressure-lowering effect of MK-927 in ocular hypertensive patients. Patients were enrolled until at least 8 "marked responders" (peak reduction in intraocular pressure comparing the MK-927-treated eye with the placebo-treated eye 6 mm Hg) and 7 "mild responders" (peak reduction in intraocular pressure comparing the MK-927-treated eye with the placebo-treated eye 3 mm Hg) were identified. In part A, 27 patients received one drop of 2% MK-927 in one eye (baseline mean ± SEM intraocular pressure, 28.0 ±1.0 mm Hg) and placebo in the contralateral eye. Intraocular pressure was measured at baseline and 1, 2, 3, 4, and 6 hours. Maximum reduction in intraocular pressure was 4.0 ±0.8 mm Hg at 3 hours, with a duration of 4 hours. Ten patients were identified as marked responders and 7 as mild responders. In part B, 8 of the marked responders entered a four-period crossover study and received 2%, 0.5%, and 0.125% MK-927 and placebo in the same treated eye as in part A, and placebo in the contralateral eye. The 7 mild responders in part C received 2% MK-927 in a similar fashion as in part A. MK-927 in concentrations of 0.125% and 0.5% had little or no effect on intraocular pressure in patients with a marked response to 2% MK-927. Within-patient variability in peak response to single doses of 2% MK-927 was substantial (coefficient of variation of 0.3 and 0.5 for marked responder and mild responder groups, respectively).

Author Affiliations
From the Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY (Drs Serie, Lustgarten, Camras, and Podos), and Merck, Sharp & Dohme Research Laboratories, West Point, Pa (Dr Lippa and Ms Panebianco).

Footnotes
Accepted for publication March 7, 1990.

Reprint requests to Mount Sinai Medical Center, Department of Ophthalmology (Box 1183), One Gustave Levy Place, New York, NY 10029 (Dr Serle).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma
Schmidt et al.
Br J Ophthalmol 1998;82:758-762.
ABSTRACT | FULL TEXT  

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys
Wang et al.
Arch Ophthalmol 1991;109:1297-1299.
ABSTRACT  

Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT  

Multiple-Dose, Dose-Response Relationship for the Topical Carbonic Anhydrase Inhibitor MK-927
Lippa et al.
Arch Ophthalmol 1991;109:46-49.
ABSTRACT